Mogamulizumab Phase III CTCL program expanded to Japan
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has added sites in Japan to the ongoing multinational Phase III clinical trial with its lead antibody mogamulizumab for cutaneous T-cell lymphoma (CTCL), firming up the likelihood of an approval submission in this market for the indication.